Abstract:Objective:To investigate the clinical characteristics, risk stratification, thrombolytic effects and prognosis of 110 patients with acute pulmonary embolism (PE) treated with thrombolysis.Methods:The clinical data of 110 patients with PE admitted to Beijing University People's Hospital from May 2009 to March 2019 were retrospective analyzed. The clinical data including general information, symptoms and signs, blood pressure, artery blood gas, coaglulation, and radiography were collected. Inclusion criteria: high-risk and intermediate high-risk group. Exclusion criteria: intermediate low-risk and low-risk group. According to the prognosis and risk stratification, the patients were divided into survival group and non-survival group, high-risk group and intermediate high-risk group. The indicators above were compared between with χ 2 test, t test or nonparametric test where appropriate. Results:Of the 110 patients with PE, 49 patients were male and 61 female with an average age of 65±16 years old; and 12 patients were in the high-risk group and 98 in the intermediate high-risk group. The respiratory rate of the high-risk group was higher, and blood pressure, PO 2, SaO 2 before thrombolysis were more lower than the intermediate high-risk group ( P<0.05). One hundred and nine patients were treated with systemic recombinant tissue plasminogen activator (rtPA), 70 patients with 50 mg, and 39 patients with 100 mg. One patient, who was contraindicated to systemic thrombolysis (with active vagina bleeding), was treated with interventional local thrombolysis; another 5 patients treated with interventional local thrombolysis because the clinical symptom were not improved markedly. One hundred and two patients survived and 8 patients died, among which, 3 patients were in the high-risk group and 5 in the intermediate high-risk group. The age, heart rate, respiration rate of the non-survival group were higher than those in the survival group, and the PO 2 before thrombolysis, PCO 2 after thrombolysis were lower ( P<0.05). Bleeding complication were occurred in 22 patients: 18 patients with minor bleeding, such as bleeding gums, skin ecchymosis, and 4 patients with moderate-severe bleeding, such as cerebral hemorrhage, abdominal bleeding, gastrointestinal bleeding, and vagina bleeding. Thirteen of 70 patients in the 50 mg group and 9 of 39 patients in the 100 mg group occurred bleeding complication. The bleeding complication of the low dose group was lower than that of the standard dose group ( P<0.05). Conclusions:Thrombolysis is first-line therapy to high-risk PE. Thrombolysis is safe and effective in the intermediate high-risk group with a lower incidence rate of bleeding complication.

Interventional Therapy of Pulmonary Thromboembolism:Technical Considerations

Comparison of Low-Molecular-weight-heparin and Unfractionated Heparin for Acute PTE

Thrombolytic Therapy of Pulmonary Thromboembolism An Analysis of Treatment in 17 Cases

Efficacy of interventional therapy on acute pulmonary embolism

Treatment Strategies for Patients with Pulmonary Thromboembolism and Contraindications to Thrombolysis

Transcatheter arterial embolization for treatment of pulmonary sequestration in pediatric patients

Interventional Therapy for High Risk Pulmonary Embolism:a Review of Ten Years

The Treatment of Acute Pulmonary Embolism in 15 Cases

Experience of Interventional Thrombolysis Therapy for Massive Pulmonary Thrombosis Embolism after Video-assisted Thoracoscopic Surgery for Lung Cancer

Clinical efficacy of interventional therapy via TIPS approach for the treatment of acute or subacute portal venous thrombosis

The Clinical Efficiency and Application Study of Comprehensive Interventional Treatment for Severe Pulmonary Embolism with Deep Vein Thrombosis

The clinical application of interventional therapy in acute pulmonary embolism

Percutaneous interventional fragmentation and thrombolysis for massive pulmonary embolism

Pulmonary Interventional Therapy for Acute Massive and Submassive Pulmonary Embolism in Cases Where Thrombolysis is Contraindicated.

Percutaneous mechanical thrombectomy combined with catheter-directed thrombolysis in the treatment of acute pulmonary embolism and lower extremity deep venous thrombosis: A novel one-stop endovascular strategy

[Efficacy and Safety of Delayed Thrombolytic Therapy for Acute Massive Pulmonary Throboembolism].

Clinical analysis of 110 cases of acute pulmonary embolism treated with thrombolysis

Interventional Treatment of Hemoptysis Associated with Pulmonary Embolism

Efficacy of percutaneous mechanical thrombus removal in acute lower extremity deep venous thrombosis

[Multicenter Clinical Trial on the Efficacy of Thrombolytic Therapy with Urokinase And/or Anticoagulant with Low Molecular Weight Heparin in Acute Pulmonary Embolism].

Clinical Feature and Diagnostic Approach to Pulmonary Thromboembolism